Ovagen
Also called EDL; Glu-Asp-Leu
A short tripeptide marketed as a liver or digestive "bioregulator." The clearest published experiments involve kidney cells and older rats, not liver disease in people.
Overview
What it is
A tripeptide of glutamic acid, aspartic acid and leucine. It is listed among the short bioregulator peptides from the originating Russian research group. It is not Livagen and not the longer AEDL sequence.
How it works
A 2014 cell study in aging kidney cells reported changes in growth and in aging markers such as p16, p21, p53 and SIRT6, plus computer modeling of peptide-DNA interaction. These suggest a mechanism to study; they do not measure symptom relief or organ recovery.
What the research shows
A 2018 study in older rats linked EDL to changes in urine output and sodium handling, interpreted as kidney protection in that model. No controlled human trial supporting liver or digestive benefits was identified.
Studied for
- Aging markers in kidney cellslab
- Kidney function in older ratsanimal
- Liver and digestive claimsnot established
Safety and regulatory status
Safety and side effects
There is no dependable list of human side effects, how often they occur, or interactions with common medications. An animal result showing no kidney toxicity does not establish safety for people with kidney disease.
Regulatory status
Not approved by the FDA for any use.
Mixing and dosing reference
Reference information only. Read before using this section.
Ovagen (20 mg Vial) Dosage Protocol
- Vial
- 20 mg Ovagen
- Add diluent
- 2 mL
- Concentration
- 10 mg/mL
- 1 unit (U-100)
- 100 mcg in 0.01 mL
- Route
- Subcutaneous
- How often
- Once per day (subcutaneous).
- Typical range
- 10–150 μg once daily (gradual titration over 16 weeks).
Standard / Gradual Approach
| Week | Daily Dose (μg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 10 μg (0.01 mg) | 0.1 units (0.001 mL) |
| Weeks 3–4 | 20 μg (0.02 mg) | 0.2 units (0.002 mL) |
| Weeks 5–6 | 50 μg (0.05 mg) | 0.5 units (0.005 mL) |
| Weeks 7–8 | 100 μg (0.1 mg) | 1 unit (0.01 mL) |
| Weeks 9–16 | 100–150 μg (0.1–0.15 mg) | 1–1.5 units (0.01–0.015 mL) |
How to mix
- Draw 2.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Dosing details
- Start: 10 μg daily for Weeks 1–2; increase to 20 μg for Weeks 3–4.
- Escalate: 50 μg for Weeks 5–6; then 100 μg for Weeks 7–8.
- Maintenance: 100–150 μg daily for Weeks 9–16.
- Frequency: Once per day (subcutaneous).
- Timing: Any consistent time; rotate injection sites.
Storage
- Lyophilized: Follow the exact product’s temperature and expiration instructions; keep the vial sealed, dry, and protected from light.
- Reconstituted: Follow formulation-specific storage and use-by instructions. Freezing or aliquoting does not by itself establish an extended shelf life.
- Avoid freeze–thaw cycles; do not assume a thawed solution remains stable or sterile without preparation-specific evidence.
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Administration technique
- Clean the vial stopper and skin with 60–70% alcohol; allow to dry.
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue.
- Do not aspirate for subcutaneous injections; inject slowly and steadily.
- Rotate sites systematically (abdomen, thighs, upper arms) to avoid tissue irritation; keep at least ~2 cm between injections on the same area.
- Use a 23–25 gauge needle (5/8″ length) or standard insulin syringe needles (28–31G).
Important notes
- Use new sterile insulin syringes (30-unit or 50-unit preferred for low-volume accuracy); dispose in a sharps container.
- Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
- Inject slowly; wait a few seconds before withdrawing the needle.
- Document daily dose and site rotation to maintain consistency.
- Label the vial with date/time of reconstitution, diluent volume, final concentration, and initials.
Protocol source: PeptideDosages.com
Common questions
Does Ovagen improve liver health?
The studies reviewed did not test that. Abnormal liver tests or ongoing digestive symptoms should be evaluated by a clinician.
Can it be combined with Livagen?
Combination safety and benefit have not been studied.
How long does it take to work?
No reliable human timeline has been established.
Related in Healthy Aging
Sources and further reading (4)
- Khavinson VK. Short peptide bioregulators and aging research. Advances in Gerontology, 2014.
- AED and EDL peptide effects in aging renal cell cultures, 2014.
- Zamorskii II, et al. Influence of peptides on the kidneys of old rats. Advances in Gerontology, 2018.
- Source summary: PeptideDosages.com research overview (rewritten for NVO).